Renal Cancer Drugs Market Research Report – Forecast to 2027

Renal Cancer Drugs Market Research Report, by Therapeutic Class (Targeted Therapy and ImmunoTherapy), Pharmacologic Class (Angiogenesis Inhibitors), Type (Clear Cell, Papillary, Oncocytic), End-Users (Hospitals &clinics) - Forecast Till 2027

ID: MRFR/Pharma/5004-HCR | | Region: Global | 100 pages

Renal Cancer Drugs Market Scenario


Renal cancer also called as kidney cancer or hypernephroma. Renal cancer is a disease in which kidney cells become malignant, the cells start proliferating out of control and start forming a tumor. Principal locations for kidney cancer are renal tube and renal pelvis. It is observed both in males and females between the age group of 50 to 80 years. The key factors responsible for influencing renal cancer drugs market are increasing use of tobacco, smoking, and increasing alcohol consumption which can also lead to cause renal cancer. Other factors of renal cancer drugs market which support to cause renal cancer are obesity and mutation in von Hippel-Lindau (VHL) gene. According to the World Cancer Research Fund, 2018 database has estimated kidney cancer is the ninth most commonly occurring cancer in men and 14th most commonly occurring cancer in women. According to the American Cancer Society in 2018, 63,340 new cases of kidney cancer are estimated in the US This is expected to provide favorable backgrounds for the renal cancer drugs market growth during the forecast period.


However, factors such as the high cost of expensive chemotherapy, increasing preference for generic drugs and side effects associated with drugs are expected to restrict the renal cancer drugs market growth during the forecast period.


Segmentation


The renal cancer drugs market is segmented on the basis of therapeutic class, pharmacologic class, type, and end-user. The renal cancer drugs market, by therapeutic class, is categorized into targeted therapy and immunotherapy. On the basis of pharmacologic class, the market is segmented into angiogenesis inhibitors, mTOR inhibitors, monoclonal antibodies and cytokine immunotherapy (IL-2). On the basis of type, the market is segmented into the clear cell, papillary, chromophobe, oncocytic, collecting duct and other. On the basis of end-user, the market is segmented hospitals and clinics, ambulatory surgical centers, diagnostic centers, research centers and other.


On the basis of region, the renal cancer drugs market is segmented into the Americas, Europe, Asia-Pacific, and the Middle East and Africa. The Americas is sub-segmented into North America and South America. The North American region is further segmented into the US and Canada. The European region is divided into two, namely, Western Europe and Eastern Europe. Western Europe is further classified into Germany, Italy, France, the UK, Spain, and the rest of Western Europe. The Asia-Pacific region is sub-segmented into Japan, China, India, Australia, the Republic of Korea, and the rest of Asia-Pacific. The Middle Eastern and African region is sub-segmented into the United Arab Emirates, Saudi Arabia, Oman, Kuwait, Qatar, and the rest of the Middle East and Africa.


Key players


Some of the key players in the global renal cancer drugs market are Novartis AG (Switzerland), Pfizer Inc. (US), GlaxoSmithKline plc (UK), Genentech, Inc. (US), F. Hoffmann-La Roche AG (Switzerland), Cipla Limited (India), Active Biotech AB (Sweden), Amgen (US), Bayer AG (Germany), Bristol-Myers Squibb company (US).


Regional Market Summary


Global Renal Cancer Drugs Market Share (%), by Region, 2017


Renal Cancer Drug Market Share


Sources: National Cancer Institute, Cancer Research UK, the American Cancer Society, Inc, US Department of Health and Human Services National Institutes of Health


It is estimated that North America dominated the global renal cancer drugs market owing to the increasing innovations in clinical practice, cancer research, and access to cancer treatment in this region. The American Cancer Society estimated about 22,660 women and 42,680 men new cases of kidney cancer in 2018 in the US This influences the market growth in North America.


Europe stood the second largest in the renal cancer drugs market owing to the increasing use of smoking and increasing tobacco usage. According to the World Health Organization’s (WHO) Fact Sheet on Tobacco and Oral Health (2018), Europe has the highest prevalence of smoking among adult population that is 28% of adults in Europe are engaged in smoking. Such a high prevalence of tobacco smoking in this region facilitates the market growth.


Asia-Pacific was projected to be the fastest growing region for the global renal cancer drugs market in 2017. The market is expected to witness growth owing to the rising prevalence of kidney cancer, changing lifestyle, and increasing tobacco use within the population. Such a high prevalence of oral cancer favors the market growth in this region. According to the National Center for Biotechnology Information, August 2016, report 121, 099 renal cancer cases were recorded in Asian countries in 2012, the number is expected to grow in coming years. This influences the market growth in this region.


The Middle East and Africa holds the least share in the global renal cancer drugs market due to the presence of poor health expenditure, low awareness, and economically diverse countries. However, the market is expected to witness growth due to increasing cancer care programs in the Middle East.


Intended Audience



  • Pharmaceutical companies

  • Biotechnological institutes

  • Government and private laboratories

  • Research and Development (R&D) companies

  • Medical research laboratories

  • Market research and consulting service providers


Market Segmentation and Key Market Players


Some of the key players in the global renal cancer drugs market are Novartis AG (Switzerland), Pfizer Inc. (US), GlaxoSmithKline plc (UK), Genentech, Inc. (US), F. Hoffmann-La Roche AG (Switzerland), Cipla Limited (India), Active Biotech AB (Sweden), Amgen (US), Bayer AG (Germany), Bristol-Myers Squibb company (US).


Renal Cancer Drugs Market, by Therapeutic Class



  • Targeted Therapy

  • ImmunoTherapy


Renal Cancer Drugs Market, by Pharmacologic Class



  • Angiogenesis Inhibitors

  • mTOR Inhibitors

  • Monoclonal Antibodies

  • Cytokine Immunotherapy (IL-2)


Renal Cancer Drugs Market, by Type



  • Clear Cell

  • Papillary

  • Chromophobe

  • Oncocytic

  • Collecting Duct

  • Othes


Renal Cancer Drugs Market, by End-Users



  • Hospitals and clinics

  • Ambulatory surgical centers

  • Diagnostic centers

  • Research centers

  • Others


Renal Cancer Drugs Market, by Region



  • Americas

  • Europe

  • Asia-Pacific

  • Middle East & Africa



Report Scope:
Report Attribute/Metric Details
  Market Size   2027: Significant Value
  CAGR   2020-2027: Substantial CAGR
  Base Year   2019
  Forecast Period   2020-2027
  Historical Data   2018
  Forecast Units   Value (USD Million)
  Report Coverage   Revenue Forecast, Competitive Landscape, Growth Factors, and Trends
  Segments Covered   Therapeutic class, Pharmacologic class, Type, and End-user
  Geographies Covered   North America, Europe, Asia-Pacific, and Rest of the World (RoW)
  Key Vendors   Novartis AG (Switzerland), Pfizer Inc. (US), GlaxoSmithKline plc (UK), Genentech, Inc. (US), F. Hoffmann-La Roche AG (Switzerland), Cipla Limited (India), Active Biotech AB (Sweden), Amgen (US), Bayer AG (Germany), Bristol-Myers Squibb company (US).
  Key Market Opportunities

  • High cost of surgical procedures
  • Expensive chemotherapy treatments
  • The side effects and reaction associated with treatments
  •   Key Market Drivers   Increasing use of tobacco, smoking, and increasing alcohol consumption


    Speak to Analyst Ask for Customization

    TABLE OF CONTENT

    Chapter 1. Report Prologue

    Chapter 2. Market Introduction

    2.1 Definition

    2.2 Scope of the Study

    2.2.1 Research Objective

    2.2.2 Assumptions

    2.2.3 Limitations

    Chapter 3. Research Methodology

    3.1 Introduction

    3.2 Primary Research

    3.3 Secondary Research

    3.4 Market Size Estimation

    Chapter 4. Market Dynamics

    4.1 Drivers

    4.2 Restraints

    4.3 Opportunities

    4.4 Challenges

    4.5 Macroeconomic Indicators

    4.6 Technology Trends & Assessment

    Chapter 5. Market Factor Analysis

    5.1 Porter’s Five Forces Analysis

    5.1.1 Bargaining Power of Suppliers

    5.1.2 Bargaining Power of Buyers

    5.1.3 Threat of New Entrants

    5.1.4 Threat of Substitutes

    5.1.5 Intensity of Rivalry

    5.2 Value Chain Analysis

    5.3 Investment Feasibility Analysis

    5.4 Pricing Analysis

    Chapter 6. Global Renal Cancer Drug Market, by Therapeutic Class

    6.1 Introduction

    6.2 Targeted Therapy

    6.3 ImmunoTherapy

    Chapter 7. Global Renal Cancer Drug Market, by Pharmacologic Class

    7.1 Introduction

    7.2 Angiogenesis Inhibitors

    7.3 mTOR Inhibitors

    7.4 Monoclonal Antibodies

    7.5 Cytokine Immunotherapy (IL-2)

    Chapter 8. Global Renal Cancer Drug Market, by Type

    8.1 Clear Cell

    8.2 Papillary

    8.3 Chromophobe

    8.4 Oncocytic

    8.5 Collecting Duct

    8.6 Other

    Chapter 9 Global Renal Cancer Drug Market, by End-Users

    9.1 Introduction

    9.2 Hospitals and clinics

    9.3 Ambulatory Surgical Centers

    9.4 Diagnostic Centers

    9.5 Research centers

    9.6 Others

    Chapter 10. Global Renal Cancer Drug Market, by Region

    10.1 Introduction

    10.2 America

    10.2.1 North America

    10.2.1.1 US

    10.2.1.2 Canada

    10.2.2 South America

    10.3 Europe

    10.3.1 Western Europe

    10.3.1.1 Germany

    10.3.1.2 France

    10.3.1.3 Italy

    10.3.1.4 Spain

    10.3.1.5 UK

    10.3.1.6 Rest of Western Europe

    10.3.2 Eastern Europe

    10.4 Asia-Pacific

    10.4.1 Japan

    10.4.2 China

    10.4.3 India

    10.4.4 Australia

    10.4.5 Republic of Korea

    10.4.6 Rest of Asia-Pacific

    10.5 Middle East & Africa

    10.5.1 United Arab Emirates

    10.5.2 Saudi Arabia

    10.5.3 Oman

    10.5.4 Kuwait

    10.5.5 Qatar

    10.5.6 Rest of the Middle East & Africa

    Chapter 11. Company Landscape

    11.1 Introduction

    11.2 Market Share Analysis

    11.3 Key Development & Strategies

    11.3.1 Key Developments

    Chapter 12 Company Profiles

    12.1 Active Biotech AB

    12.1.1 Company Overview

    12.1.2 End-Users Overview

    12.1.3 Financials

    12.2.4 Key Developments

    12.1.5 SWOT Analysis

    12.2 Amgen

    12.2.1 Company Overview

    12.2.2 End-Users Overview

    12.2.3 Financial Overview

    12.2.4 Key Developments

    12.2.5 SWOT Analysis

    12.3 GlaxoSmithKline Plc.

    12.3.1 Company Overview

    12.3.2 End-Users Overview

    12.3.3 Financial Overview

    12.3.4 Key Development

    12.3.5 SWOT Analysis

    12.4 Genentech, Inc.

    12.4.1 Company Overview

    12.4.2 End-Users/Business Segment Overview

    12.4.3 Financial Overview

    12.4.4 Key Development

    12.4.5 SWOT Analysis

    12.5 F. Hoffmann-La Roche AG

    12.5.1 Company Overview

    12.5.2 End-Users Overview

    12.5.3 Financial overview

    12.5.4 Key Developments

    12.5.5 SWOT Analysis

    12.6 Cipla Limited

    12.6.1 Company Overview

    12.6.2 End-Users Overview

    12.6.3 Financial Overview

    12.6.4 Key Developments

    12.6.5 SWOT Analysis

    11.7 Active Biotech AB

    12.7.1 Overview

    12.7.2 End-Users Overview

    12.7.3 Financials

    12.7.4 Key Developments

    12.7.5 SWOT Analysis

    12.8 AMGEN

    12.8.1 Overview

    12.8.2 End-Users Overview

    12.8.3 Financials

    12.8.4 Key Developments

    12.8.5 SWOT Analysis

    12.9 Bayer AG

    12.9.1Overview

    12.8.2 End-Users Overview

    12.8.3 Financials

    12.8.4 Key Developments

    12.8.5 SWOT Analysis

    12.10 Bristol-Myers Squibb company

    12.10.1Overview

    12.10.2 End-Users Overview

    12.10.3 Financials

    12.10.4 Key Developments

    12.10.5 SWOT Analysis

    12.12 Others

    Chapter 13 Appendix

    LIST OF TABLES

    Table 1 Global Renal Cancer Drug Market Industry Synopsis, 2020–2027

    Table 2 Global Renal Cancer Drug Market Estimates & Forecast, 2020–2027, (USD Million)

    Table 3 Global Renal Cancer Drug Market, by Region, 2020–2027, (USD Million)

    Table 4 Global Renal Cancer Drug Market, by Therapeutic Class, 2020–2027, (USD Million)

    Table 5 Global Renal Cancer Drug Market, by Pharmacologic Class, 2020–2027, (USD Million)

    Table 6 Global Renal Cancer Drug Market, by Type, 2020–2027, (USD Million)

    Table 7 Global Renal Cancer Drug Market, by End-Users, 2020–2027, (USD Million)

    Table 8 North America: Global Renal Cancer Drug Market, by Therapeutic Class, 2020–2027, (USD Million)

    Table 9 North America: Global Renal Cancer Drug Market, by Pharmacologic Class, 2020–2027, (USD Million)

    Table 10 North America: Global Renal Cancer Drug Market, by Type, 2020–2027, (USD Million)

    Table 11 North America: Global Renal Cancer Drug Market, by End-Users, 2020–2027, (USD Million)

    Table 12 US: Global Renal Cancer Drug Market, by Therapeutic Class, 2020–2027, (USD Million)

    Table 13 US: Global Renal Cancer Drug Market, by Pharmacologic Class, 2020–2027, (USD Million)

    Table 14 US: Global Renal Cancer Drug Market, by Type, 2020–2027, (USD Million

    Table 15 US: Global Renal Cancer Drug Market, by End-Users, 2020–2027, (USD Million)

    Table 16 Canada: Global Renal Cancer Drug Market, by Therapeutic Class, 2020–2027, (USD Million)

    Table 17 Canada: Global Renal Cancer Drug Market, by Pharmacologic Class, 2020–2027, (USD Million)

    Table 18 Canada: Global Renal Cancer Drug Market, by Type, 2020–2027, (USD Million)

    Table 19 Canada: Global Renal Cancer Drug Market, by End-Users, 2020–2027, (USD Million)

    Table 20 South America: Global Renal Cancer Drug Market, by Therapeutic Class, 2020–2027, (USD Million)

    Table 21 South America: Global Renal Cancer Drug Market, by Pharmacologic Class, 2020–2027, (USD Million)

    Table 22 South America: Global Renal Cancer Drug Market, by Type, 2020–2027, (USD Million)

    Table 23 South America: Global Renal Cancer Drug Market, by End-Users, 2020–2027, (USD Million)

    Table 24 Europe: Global Renal Cancer Drug Market, Therapeutic Class, 2020–2027, (USD Million)

    Table 25 Europe: Global Renal Cancer Drug Market, by Pharmacologic Class, 2020–2027, (USD Million)

    Table 26 Europe: Global Renal Cancer Drug Market, by Type, 2020–2027, (USD Million)

    Table 27 Europe: Global Renal Cancer Drug Market, by End-Users, 2020–2027, (USD Million)

    Table 28 Western Europe: Global Renal Cancer Drug Market, by Therapeutic Class, 2020–2027, (USD Million)

    Table 29 Western Europe: Global Renal Cancer Drug Market, by Pharmacologic Class, 2020–2027, (USD Million)

    Table 30 Western Europe: Global Renal Cancer Drug Market, by Type, 2020–2027, (USD Million)

    Table 31 Western Europe: Global Renal Cancer Drug Market, by End-Users, 2020–2027, (USD Million)

    Table 32 Eastern Europe: Global Renal Cancer Drug Market, by Therapeutic Class, 2020–2027, (USD Million)

    Table 33 Eastern Europe: Global Renal Cancer Drug Market, by Pharmacologic Class, 2020–2027, (USD Million)

    Table 34 Eastern Europe: Global Renal Cancer Drug Market, by Type, 2020–2027, (USD Million)

    Table 35 Eastern Europe: Global Renal Cancer Drug Market, by End-Users, 2020–2027, (USD Million)

    Table 36 Asia-Pacific: Global Renal Cancer Drug Market, by Therapeutic Class, 2020–2027, (USD Million)

    Table 37 Asia-Pacific: Global Renal Cancer Drug Market, by Pharmacologic Class, 2020–2027, (USD Million)

    Table 38 Asia-Pacific: Global Renal Cancer Drug Market, by Type, 2020–2027, (USD Million)

    Table 39 Asia-Pacific: Global Renal Cancer Drug Market, by End-Users, 2020–2027, (USD Million)

    Table 31 Middle East & Africa: Global Renal Cancer Drug Market, by Therapeutic Class,2020-2027,(USD Million)

    Table 32 Middle East & Africa: Global Renal Cancer Drug Market, by Pharmacologic Class, 2020–2027, (USD Million)

    Table 33 Middle East & Africa: Global Renal Cancer Drug Market, by Type, 2020–2027, (USD Million)

    Table 34 Middle East & Africa: Global Renal Cancer Drug Market, by End-Users, 2020–2027, (USD Million)

    LIST OF FIGURES

    Figure 1 Research Process

    Figure 2 Segmentation for the Global Renal Cancer Drug Market

    Figure 3 Market Dynamics for the Global Renal Cancer Drug Market

    Figure 4 Global Renal Cancer Drug Market Share, by Therapeutic Class 2020

    Figure 6 Global Renal Cancer Drug Market Share, by Pharmacologic Class, 2020

    Figure 7 Global Renal Cancer Drug Market Share, by Type, 2020

    Figure 8 Global Renal Cancer Drug Market Share, by End-Users, 2020

    Figure 9 Global Renal Cancer Drug Market Share, by Region, 2020

    Figure 10 North America Global Renal Cancer Drug Market Share, by Country, 2020

    Figure 11 Europe Prescribed Health Apps Share, by Country, 2020

    Figure 12 Asia-Pacific Global Renal Cancer Drug Market Share, by Country, 2020

    Figure 13 Middle East & Africa Global Renal Cancer Drug Market Share, by Country, 2020

    Figure 14 Global Renal Cancer Drug Market: Company Share Analysis, 2020 (%)

    Figure 15 Novartis AG: Key Financials

    Figure 16 Novartis AG: Segmental Revenue

    Figure 17 Novartis AG: Geographical Revenue

    Figure 18 Pfizer Inc.: Key Financials

    Figure 19 Pfizer Inc.: Segmental Revenue

    Figure 20 Pfizer Inc.: Geographical Revenue

    Figure 21 GlaxoSmithKline plc: Key Financials

    Figure 22 GlaxoSmithKline plc.: Segmental Revenue

    Figure 23 GlaxoSmithKline plc.: Geographical Revenue

    Figure 24 Genentech, Inc.: Key Financials

    Figure 25 Genentech, Inc.: Segmental Revenue

    Figure 26 Genentech, Inc.: Geographical Revenue

    Figure 27 F. Hoffmann-La Roche AG: Key Financials

    Figure 28 F. Hoffmann-La Roche AG: Segmental Revenue

    Figure 29 F. Hoffmann-La Roche AG: Geographical Revenue

    Figure 30 Cipla Limited: Key Financials

    Figure 31 Cipla Limited: Segmental Revenue

    Figure 32 Cipla Limited: Geographical Revenue

    Figure 33 Active Biotech AB: Key Financials

    Figure 34 Active Biotech AB: Segmental Revenue

    Figure 35 Active Biotech AB: Geographical Revenue

    Figure 36 Amgen: Key Financials

    Figure 37 Amgen: Segmental Revenue

    Figure 38 Amgen: Geographical Revenue

    Figure 39 Bayer AG: Key Financials

    Figure 40 Bayer AG: Segmental Revenue

    Figure 41 Bayer AG: Geographical Revenue

    Figure 42 Bristol-Myers Squibb company: Key Financials

    Figure 43 Bristol-Myers Squibb company: Segmental Revenue

    Figure 44 Bristol-Myers Squibb company: Geographical Revenue